



Nabriva Therapeutics Dublin, Ireland www.nabriva.com

¹Summa Health, Akron, OH, USA; ²Nabriva Therapeutics US, Inc., King of Prussia, PA, USA; ⁴EGS Consulting, Ardmore, PA, USA; ⁵Talbot Advisors LLC, Anna Maria, FL, USA

INTRODUCTION

- Community-acquired pneumonia (CAP) causes significant morbidity, mortality, and a substantial economic burden¹
- The estimated incidence of CAP ranges from 1.7 to 11.6 cases per 1000 person-years in Europe and ~10.6 cases per 1000 person-years in the United States^{2,3}
- CAP costs are ~€10.1 billion annually in Europe and over \$17 billion annually in the United States^{4,5}
- Streptococcus pneumoniae and Haemophilus influenzae are the most frequently isolated bacterial CAP pathogens⁴
- New therapies for community-acquired bacterial pneumonia (CABP) are needed because of the rise of antibacterial resistance, the intrinsic antimicrobial resistance of certain pathogens, and because current treatments have undesirable risks and side effects⁶⁻⁸
- Lefamulin is a novel semi-synthetic pleuromutilin antibiotic in development for the treatment of CABP. Lefamulin inhibits protein synthesis by binding selectively and specifically to the peptidyl transferase center of the 50S ribosomal subunit⁹
- Lefamulin shows potent in vitro activity against CABP-associated pathogens (S. pneumoniae, H. influenzae, Moraxella catarrhalis, Staphylococcus aureus, Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella pneumophila); its activity is unaffected by an organism's resistance to other major antibiotic classes¹⁰⁻¹³
- Lefamulin rapidly and predictably penetrates target sites including plasma and the epithelial lining fluid (ELF) of the lungs. Unbound lefamulin levels in ELF are 5.7-fold higher than in plasma, making it an ideal candidate for CABP therapy¹⁴

OBJECTIVE

• To describe the primary outcomes of the first phase 3 trial of lefamulin as monotherapy in adult patients with CABP

METHODS

Study Design

- LEAP1 was a prospective, multicenter, randomized, double-blind, double-dummy, noninferiority phase 3 study to evaluate adult patients with CABP conducted in 18 countries at 104 study sites (Figure 1)
- Patients were randomized to receive lefamulin 150 mg intravenously (IV) every 12 hours (q12h) or moxifloxacin 400 mg IV every 24 hours (q24h) for 7 days of therapy
- If methicillin-resistant S. aureus (MRSA) was suspected at screening, linezolid (600 mg IV q12h) or placebo was added to moxifloxacin or lefamulin therapy, respectively; if MRSA was confirmed, treatment would continue for 10 days of total therapy, with the following modifications:
- If MRSA was confirmed during the IV treatment period, patients on moxifloxacin plus linezolid discontinued moxifloxacin and instead received only linezolid. Patients randomized to receive lefamulin continued on lefamulin but discontinued linezolid placebo
- If MRSA was confirmed during the oral treatment period, those on moxifloxacin plus linezolid discontinued moxifloxacin and continued to receive linezolid plus lefamulin placebo. Those randomized to lefamulin continued with this therapy and discontinued moxifloxacin placebo
- If MRSA was suspected but cultures were negative, linezolid or matching placebo was discontinued, and the patient continued with moxifloxacin or lefamulin
- Patients could be switched to oral therapy (lefamulin 600 mg q12h or moxifloxacin 400 mg q24h ± linezolid 600 mg q12h) after ≥6 IV doses of study drug (~3 days) if they met the following predefined criteria: were hemodynamically stable, had a normalizing temperature <38.0°C (<100.4°F) in the previous 24 hours, showed improvement by 1 severity category in \geq 2 of 4 cardinal CABP symptoms, and could swallow oral medications

Patients

- Patients ≥18 years old with CABP (Pneumonia Outcomes Research Team [PORT] risk class III [limited to 75%], IV, or V) were eligible
- A single dose of short-acting antibiotic (as requiring >1 dose per day), within 24 hours of randomization, was allowed in up to 25% of the population
- Informed consent and approval of study procedures were provided in accordance with local regulations before enrollment

Assessments

- than –12.5%

Figure 1. Study Design



CABP=community-acquired bacterial pneumonia; CE-TOC=clinically evaluable at TOC; EMA=European Medicines Agency; EOT=end of treatment; FDA=US Food and Drug Administration: ITT=intent-to-treat; IV=intravenous; mITT=modified ITT; TOC=test of cure. *If MRSA was suspected, linezolid or placebo was added to moxifloxacin or lefamulin therapy, respectively, for 10 days of total therapy. [†]EOT assessment was within 2 days after the last dose of study drug.

RESULTS

Patients

- moxifloxacin ± linezolid (Figure 2)
- in the lefamulin group (Table 1)
- (4.4% [14/318])

Lefamulin Is Noninferior to Moxifloxacin in Adults With **Community-Acquired Bacterial Pneumonia: Phase 3** Lefamulin Evaluation Against Pneumonia (LEAP 1) Study

Thomas File,¹ Lisa Goldberg,² Anita Das,³ Carolyn Sweeney,² John Saviski,² Steven P. Gelone,² Elyse Seltzer,⁴ George H Talbot,⁵ Leanne B. Gasink²

METHODS (continued)

Screening occurred within 24 hours before the first dose of study drug

 Early clinical response (ECR), the US Food and Drug Administration (FDA) primary endpoint, was assessed in the intent-to-treat (ITT) population 72–120 hours after the first dose of study drug - ECR was achieved if (1) a patient showed improvement in ≥ 2 of 4 CABP signs or symptoms (dyspnea, cough, production of purulent sputum, chest pain), (2) had no worsening in any signs or symptoms, (3) was alive, and (4) did not receive nonstudy antibacterial therapy for CABP Noninferiority of lefamulin for the FDA primary endpoint was concluded if the lower limit of the 2-sided 95% CI for the observed difference in ECR rates between treatment groups was greater

Investigator assessment of clinical response (IACR), the European Medicines Agency (EMA) primary endpoint, was evaluated at the test of cure (TOC) assessment 5–10 days after the last dose of study drug in the modified ITT (mITT) population (patients who received any amount of study drug) and in the clinically evaluable (CE) population (patients that met pre-defined specified criteria related to adherence to the protocol)

IACR was classified as successful if the signs and symptoms of CABP resolved or improved such that no additional antibacterial therapy was administered for the treatment of CABP. IACR failure occurred if (1) the signs and symptoms of CABP did not resolve or improve, or worsened, such that nonstudy antibacterial therapy was administered for the treatment of CABP, (2) death occurred, or (3) an adverse event led to study drug discontinuation and institution of nonstudy antibacterial therapy for the treatment of CABP

Noninferiority of lefamulin for the EMA primary endpoints was concluded if the lower limit of the 2-sided 95% CI for the observed difference in IACR rates between the treatment groups was greater than –10% for both the mITT and CE populations

Of the 551 patients enrolled, 276 were randomized to receive lefamulin and 275 to receive

Patient characteristics were similar between the 2 groups; however, there were more older patients

• S. pneumoniae was the most commonly isolated bacterium, being isolated from 59.7% (190/318) of patients with available microbiological data (the microbiological ITT [microITT] population), followed by *H. influenzae* (34.0% [108/318]), *M. pneumoniae* (12.3% [39/318]), *M. catarrhalis* (11.3% [36/318]), L. pneumophila (10.1% [32/318]), C. pneumoniae (9.4% [30/318]), and S. aureus

The distribution of baseline pathogens was similar between the treatment groups

RESULTS (continued)

Figure 2. Patient Disposition



CABP=community-acquired bacterial pneumonia; CE-TOC=clinically evaluable at TOC; EOT=end of treatment; IACR=investigator assessment of clinical response; ITT=intent-to-treat; mITT=modified ITT; MRSA=methicillin-resistant Staphylococcus aureus; TOC=test of cure Met the criteria for CABP, received at least the prespecified minimal amount of the intended dose of study drug and duration of treatment, IACR not indeterminate, did not receive concomitant antibacterial therapy (other than adjunctive linezolid) potentially effective against CABP pathogens (except in the case of clinical failure), and had no other confounding factors that interfered with outcome assessment.

Table 1. Patient Characteristics

	Leramuin		
Characteristic	<i>n</i> =276	<i>n</i> =275	
Mean age, y	61.0	59.6	
Patients, n (%)			
<65 y	144 (52.2)	167 (60.7)	
65–74 y	74 (26.8)	66 (24.0)	
≥75 y	58 (21.0)	42 (15.3)	
Sex, n (%)			
Male	170 (61.6)	160 (58.2)	
Mean BMI, kg/m ²	26.48	26.33	
Race, <i>n</i> (%)			
White	239 (86.6)	239 (86.9)	
Asian	24 (8.7)	20 (7.3)	
Black	11 (4.0)	12 (4.4)	
American Indian or Alaska Native	0	1 (0.4)	
Other	2 (0.7)	3 (1.1)	
PORT class, n (%)			
II	0	1 (0.4)	
	196 (71.0)	201 (73.1)	
IV	76 (27.5)	70 (25.5)	
V	4 (1.4)	3 (1.1)	
Renal status, n (%)			
Severe impairment (CrCl <30 mL/min)	3 (1.1)	3 (1.1)	
Moderate impairment (CrCl 30-<60 mL/min)	61 (22.1)	62 (22.5)	
Mild impairment (CrCl 60–<90 mL/min)	89 (32.2)	75 (27.3)	
Normal function (CrCl ≥90 mL/min)	121 (43.8)	134 (48.7)	

BMI=body mass index; CrCI=creatinine clearance; PORT=Pneumonia Outcomes Research Team.

Early Clinical Response and Investigator Assessment of Clinical Response

• For the FDA primary endpoint, lefamulin was noninferior (12.5% margin) to moxifloxacin ± linezolid (Figure 3)

Figure 3. FDA Primary Endpoint of ECR



ECR=early clinical response; ITT=intent to treat.

• Lefamulin demonstrated noninferiority to moxifloxacin ± linezolid for the EMA primary endpoint (10% margin) in both mITT and CE-TOC populations (Figure 4)

Figure 4. EMA Primary Endpoint of IACR in the (A) mITT and (B) IACR CE-TOC **Populations**



CE-TOC=clinically evaluable at test of cure; IACR=investigator assessment of clinical response; mITT=modified intent-to-treat.

22nd Annual Making a Difference in Infectious Diseases (MAD-ID) Meeting; May 8–11, 2019; Orlando, FL, USA

Clinical Efficacy by PORT Classification

 Lefamulin demonstrated high ECR and IACR rates across the 3 PORT-defined severities of CABP (Table 2)

Table 2. Response by PORT Classification

	ECR ITT			IACR mITT			
PORT Class	Lefamulin <i>n</i> =276	Moxifloxacin ± Linezolid <i>n</i> =275	Treatment Difference (95% CI)	Lefamulin <i>n</i> =273	Moxifloxacin ± Linezolid <i>n</i> =273	Treatment Difference (95% CI)	
П	0	1/1 (100%)		0	1/1 (100%)	_	
Ш	175/196	187/201	-3.7	163/194	168/200	0.0	
	(89.3%)	(93.0%)	(-9.8, 2.3)	(84.0%)	(84.0%)	(–7.7, 7.8)	
IV	63/76	57/70	1.5	57/75	58/69	-8.1	
	(82.9%)	(81.4%)	(–12.3, 15.3)	(76.0%)	(84.1%)	(-22.4, 6.3)	
V	3/4	3/3	-25.0	3/4	3/3	-25.0	
	(75.0%)	(100%)	(-96.6, 46.6)	(75.0%)	(100%)	(-96.6, 46.6)	

ECR=early clinical response; IACR=investigator assessment of clinical response; mITT=modified intent-to-treat; PORT=Pneumonia Outcomes

Safety and Tolerability

• The safety and tolerability profile of lefamulin was generally comparable to that of moxifloxacin ± linezolid

CONCLUSIONS

- In this phase 3 study in CABP, lefamulin demonstrated high response rates for ECR and IACR that were noninferior to the comparator, moxifloxacin (standard of care) ± linezolid
- Response rates were high across pneumonia severities as assessed by PORT scores
- Lefamulin shows promise as an empiric and targeted monotherapy with an IV to oral option for the treatment of CABP in adults

REFERENCES

- (1) Ramirez JA and Anzueto AR. J Antimicrob Chemothe 2011;66 suppl 3:iii3-9.
- (2) Broulette J, et al. Am Health Drug Benefits. 2013;6(8):494-503.
- (3) Gibson J. The European Lung White Book: Respiratory Health and Disease in Europe. 2nd ed. Sheffield: Europear Respiratory Society; 2013.
- (4) Welte T, et al. *Thorax*. 2012;67(1):71-79.
- (5) File TM and Marrie TJ. Postgrad Med. 2010;122(2):130-141.
- (6) Pereyre S, et al. *Front Microbiol*. 2016;7:974.
- (7) Cunha BA. *Chest*. 2004;125(5):1913-1919.
- (8) Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2013. US Department of Health and Human Services. Available at: https://www.cdc.gov/drugresistance/threat-report-2013/index. html. Accessed March 12, 2018.

Acknowledgments & Disclosures

- (9) Eyal Z, et al. Sci Rep. 2016;6:39004.
- (10) Sader HS, et al. Antimicrob Agents Chemother. 2012;56(3):1619-1623.
- (11) Sader HS, et al. J Antimicrob Chemother. 2012;67(5):1170-1175.
- 2) Paukner S, et al. Antimicrob Agents Chemother. 2013;57(9):4489-4495.
- (13) Waites KB, et al. Antimicrob Agents Chemother. 2017;61(2):doi:10.1128/AAC.02008-02016
- (14) Zeitlinger M, et al. J Antimicrob Chemother. 2016;71(4):1022-1026.

Funding for development of this poster was provided by Nabriva to C4 MedSolutions, LLC (Yardley, PA), a CHC Group company. Lisa Goldberg, Carolyn Sweeney, Steven P. Gelone, John Saviski, Elyse Seltzer, and Leanne B Gasink are or were employees of Nabriva when the study was performed. Anita Das and George H. Talbot served as consultants for Nabriva during design and execution of the study, and George H. Talbot is a member of Nabriva's Board of Directors. Thomas File has served as a consultant for Motif BioSciences, Allergan, Medicines Company, Merck, Nabriva, Paratek, and Cempra.



Scan this QR code with your electronic device to receive a PDF file of the poster or visit posters.chcinc.com/MADIDLEAP1